GB9924361D0 - Purine derivatives - Google Patents

Purine derivatives

Info

Publication number
GB9924361D0
GB9924361D0 GBGB9924361.0A GB9924361A GB9924361D0 GB 9924361 D0 GB9924361 D0 GB 9924361D0 GB 9924361 A GB9924361 A GB 9924361A GB 9924361 D0 GB9924361 D0 GB 9924361D0
Authority
GB
United Kingdom
Prior art keywords
purine derivatives
purine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9924361.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Priority to GBGB9924361.0A priority Critical patent/GB9924361D0/en
Publication of GB9924361D0 publication Critical patent/GB9924361D0/en
Priority to PA20008503601A priority patent/PA8503601A1/es
Priority to SK474-2002A priority patent/SK4742002A3/sk
Priority to CA002387533A priority patent/CA2387533C/fr
Priority to GE4727A priority patent/GEP20043324B/en
Priority to BR0014760-5A priority patent/BR0014760A/pt
Priority to APAP/P/2002/002480A priority patent/AP2002002480A0/en
Priority to NZ517294A priority patent/NZ517294A/en
Priority to PL00354880A priority patent/PL354880A1/xx
Priority to ES00962773T priority patent/ES2257317T3/es
Priority to EA200200360A priority patent/EA004985B1/ru
Priority to EP00962773A priority patent/EP1220862B1/fr
Priority to AU74412/00A priority patent/AU771531B2/en
Priority to EEP200200194A priority patent/EE200200194A/xx
Priority to JP2001530349A priority patent/JP3994008B2/ja
Priority to TR2002/01001T priority patent/TR200201001T2/xx
Priority to OA1200200103A priority patent/OA12060A/en
Priority to CNB008141762A priority patent/CN1166678C/zh
Priority to MXPA02003750A priority patent/MXPA02003750A/es
Priority to HU0203485A priority patent/HUP0203485A3/hu
Priority to PCT/IB2000/001446 priority patent/WO2001027131A1/fr
Priority to IL14833100A priority patent/IL148331A0/xx
Priority to DE60026861T priority patent/DE60026861T2/de
Priority to CZ20021179A priority patent/CZ20021179A3/cs
Priority to AT00962773T priority patent/ATE321065T1/de
Priority to KR1020027004766A priority patent/KR20030022758A/ko
Priority to GT200000170A priority patent/GT200000170A/es
Priority to EC2000003713A priority patent/ECSP003713A/es
Priority to MYPI20004789A priority patent/MY141512A/en
Priority to GT200000173A priority patent/GT200000173A/es
Priority to CO00077983A priority patent/CO5261621A1/es
Priority to ARP000105422A priority patent/AR026052A1/es
Priority to TNTNSN00203A priority patent/TNSN00203A1/fr
Priority to SV2000000199A priority patent/SV2002000199A/es
Priority to PE2000001099A priority patent/PE20010753A1/es
Priority to US09/688,497 priority patent/US6448236B1/en
Priority to IS6287A priority patent/IS6287A/is
Priority to CR6607A priority patent/CR6607A/es
Priority to BG106567A priority patent/BG106567A/xx
Priority to ZA200202725A priority patent/ZA200202725B/en
Priority to MA26591A priority patent/MA26829A1/fr
Priority to NO20021751A priority patent/NO20021751L/no
Priority to HR20020325A priority patent/HRP20020325A2/xx
Priority to HK03100163.8A priority patent/HK1047942B/zh
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
GBGB9924361.0A 1999-10-14 1999-10-14 Purine derivatives Ceased GB9924361D0 (en)

Priority Applications (44)

Application Number Priority Date Filing Date Title
GBGB9924361.0A GB9924361D0 (en) 1999-10-14 1999-10-14 Purine derivatives
PA20008503601A PA8503601A1 (es) 1999-10-14 2000-09-26 Derivados de purina
DE60026861T DE60026861T2 (de) 1999-10-14 2000-10-06 Purin-derivate
PCT/IB2000/001446 WO2001027131A1 (fr) 1999-10-14 2000-10-06 Derives de la purine
CZ20021179A CZ20021179A3 (cs) 1999-10-14 2000-10-06 Purinové deriváty
GE4727A GEP20043324B (en) 1999-10-14 2000-10-06 Purine Derivatives
CA002387533A CA2387533C (fr) 1999-10-14 2000-10-06 Derives de la purine
APAP/P/2002/002480A AP2002002480A0 (en) 1999-10-14 2000-10-06 Purine derivatives.
NZ517294A NZ517294A (en) 1999-10-14 2000-10-06 Purine derivatives
PL00354880A PL354880A1 (en) 1999-10-14 2000-10-06 Purine derivatives
ES00962773T ES2257317T3 (es) 1999-10-14 2000-10-06 Derivados de purina.
EA200200360A EA004985B1 (ru) 1999-10-14 2000-10-06 Производные пурина
EP00962773A EP1220862B1 (fr) 1999-10-14 2000-10-06 Derives de la purine
AU74412/00A AU771531B2 (en) 1999-10-14 2000-10-06 Purine derivatives
EEP200200194A EE200200194A (et) 1999-10-14 2000-10-06 Puriinderivaadid
JP2001530349A JP3994008B2 (ja) 1999-10-14 2000-10-06 プリン誘導体
TR2002/01001T TR200201001T2 (tr) 1999-10-14 2000-10-06 Pürin türevleri
OA1200200103A OA12060A (en) 1999-10-14 2000-10-06 Purine derivatives.
AT00962773T ATE321065T1 (de) 1999-10-14 2000-10-06 Purin-derivate
MXPA02003750A MXPA02003750A (es) 1999-10-14 2000-10-06 Derivados de purina.
HU0203485A HUP0203485A3 (en) 1999-10-14 2000-10-06 Purine derivatives
SK474-2002A SK4742002A3 (en) 1999-10-14 2000-10-06 Purine derivatives
IL14833100A IL148331A0 (en) 1999-10-14 2000-10-06 Purine derivatives
KR1020027004766A KR20030022758A (ko) 1999-10-14 2000-10-06 퓨린 유도체
BR0014760-5A BR0014760A (pt) 1999-10-14 2000-10-06 Derivados de purina
CNB008141762A CN1166678C (zh) 1999-10-14 2000-10-06 嘌呤衍生物
GT200000170A GT200000170A (es) 1999-10-14 2000-10-10 Agentes terapeuticos.
CO00077983A CO5261621A1 (es) 1999-10-14 2000-10-12 Derivados de purina
EC2000003713A ECSP003713A (es) 1999-10-14 2000-10-12 Derivados de purina
MYPI20004789A MY141512A (en) 1999-10-14 2000-10-12 Purine derivatives
GT200000173A GT200000173A (es) 1999-10-14 2000-10-12 Derivados de purina.
PE2000001099A PE20010753A1 (es) 1999-10-14 2000-10-13 DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a
SV2000000199A SV2002000199A (es) 1999-10-14 2000-10-13 Derivados de purina ref.pcs10352aajr/bb
ARP000105422A AR026052A1 (es) 1999-10-14 2000-10-13 Derivados de purina
TNTNSN00203A TNSN00203A1 (fr) 1999-10-14 2000-10-13 Derives de purine nouveaux, procede pour leur preparation et des compositions les contenant
US09/688,497 US6448236B1 (en) 1999-10-14 2000-10-16 Purine derivatives
IS6287A IS6287A (is) 1999-10-14 2002-02-26 Púrín afleiður
CR6607A CR6607A (es) 1999-10-14 2002-03-11 Derivados de purina
BG106567A BG106567A (en) 1999-10-14 2002-04-02 Purine derivatives
ZA200202725A ZA200202725B (en) 1999-10-14 2002-04-08 Purine derivatives.
MA26591A MA26829A1 (fr) 1999-10-14 2002-04-09 Derives de purines
NO20021751A NO20021751L (no) 1999-10-14 2002-04-12 Purinderivater
HR20020325A HRP20020325A2 (en) 1999-10-14 2002-04-12 Purine derivatives
HK03100163.8A HK1047942B (zh) 1999-10-14 2003-01-07 嘌呤衍生物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9924361.0A GB9924361D0 (en) 1999-10-14 1999-10-14 Purine derivatives

Publications (1)

Publication Number Publication Date
GB9924361D0 true GB9924361D0 (en) 1999-12-15

Family

ID=10862758

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9924361.0A Ceased GB9924361D0 (en) 1999-10-14 1999-10-14 Purine derivatives

Country Status (43)

Country Link
US (1) US6448236B1 (fr)
EP (1) EP1220862B1 (fr)
JP (1) JP3994008B2 (fr)
KR (1) KR20030022758A (fr)
CN (1) CN1166678C (fr)
AP (1) AP2002002480A0 (fr)
AR (1) AR026052A1 (fr)
AT (1) ATE321065T1 (fr)
AU (1) AU771531B2 (fr)
BG (1) BG106567A (fr)
BR (1) BR0014760A (fr)
CA (1) CA2387533C (fr)
CO (1) CO5261621A1 (fr)
CR (1) CR6607A (fr)
CZ (1) CZ20021179A3 (fr)
DE (1) DE60026861T2 (fr)
EA (1) EA004985B1 (fr)
EC (1) ECSP003713A (fr)
EE (1) EE200200194A (fr)
ES (1) ES2257317T3 (fr)
GB (1) GB9924361D0 (fr)
GE (1) GEP20043324B (fr)
GT (2) GT200000170A (fr)
HK (1) HK1047942B (fr)
HR (1) HRP20020325A2 (fr)
HU (1) HUP0203485A3 (fr)
IL (1) IL148331A0 (fr)
IS (1) IS6287A (fr)
MA (1) MA26829A1 (fr)
MX (1) MXPA02003750A (fr)
MY (1) MY141512A (fr)
NO (1) NO20021751L (fr)
NZ (1) NZ517294A (fr)
OA (1) OA12060A (fr)
PA (1) PA8503601A1 (fr)
PE (1) PE20010753A1 (fr)
PL (1) PL354880A1 (fr)
SK (1) SK4742002A3 (fr)
SV (1) SV2002000199A (fr)
TN (1) TNSN00203A1 (fr)
TR (1) TR200201001T2 (fr)
WO (1) WO2001027131A1 (fr)
ZA (1) ZA200202725B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0015727D0 (en) * 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US20050033044A1 (en) * 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
AU2005226359B2 (en) 2004-03-26 2011-02-03 Astrazeneca Aktiebolag 9-substituted 8-oxoadenine compound
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EA011826B1 (ru) 2004-05-26 2009-06-30 Инотек Фармасьютикалз Корпорейшн Пуриновые производные в качестве агонистов аденозиновых арецепторов и способы их применения
EP1802316B1 (fr) * 2004-09-20 2011-11-02 Inotek Pharmaceuticals Corporation Dérivés de la purine et leurs procédés d'utilisation
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2532679B1 (fr) 2005-10-21 2017-04-12 Novartis AG Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques
JP5203214B2 (ja) * 2005-11-30 2013-06-05 イノテック ファーマシューティカルズ コーポレイション プリン化合物およびその使用方法
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
MY146645A (en) * 2006-04-21 2012-09-14 Novartis Ag Purine derivatives for use as adenosin a2a receptor agonists
WO2008004948A1 (fr) 2006-07-05 2008-01-10 Astrazeneca Ab Dérivés de la 8-oxoadénine agissant comme modulateurs de tlr7
CA2664378A1 (fr) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines utilisees comme inhibiteurs des lipides kinases pl3k
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
JP2010520254A (ja) * 2007-03-02 2010-06-10 グラクソ グループ リミテッド システインプロテアーゼ阻害剤としてのプリン類
PT2132209E (pt) * 2007-03-19 2014-04-15 Astrazeneca Ab Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7)
WO2008114006A1 (fr) * 2007-03-19 2008-09-25 Astrazeneca Ab Composés de 8 oxo-adenine 9 substitué comme modulateurs du récepteur de type toll (tlr7)
PE20081887A1 (es) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
EP2138497A4 (fr) 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co Nouveau composé d'adénine
PL2155743T3 (pl) * 2007-05-08 2013-01-31 Astrazeneca Ab Imidazochinoliny o właściwościach immunomodulacyjnych
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
US20110054168A1 (en) * 2008-01-17 2011-03-03 Ayumu Kurimoto Method for preparing adenine compound
EP2246353A4 (fr) 2008-01-17 2011-04-20 Dainippon Sumitomo Pharma Co Procédé de production d'un composé d'adénine
WO2010088335A1 (fr) 2009-01-29 2010-08-05 Novartis Ag Benzimidazoles substitués destinés au traitement d'astrocytomes
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
BR112012003709B1 (pt) 2009-08-17 2021-05-18 Intellikine Llc compostos heterocíclicos e usos dos mesmos
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
WO2011068233A1 (fr) * 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines agissant par l'intermédiaire des récepteurs de type toll (tlr)
SI2523669T1 (sl) 2010-01-11 2017-05-31 Inotek Pharmaceuticals Corporation Kombinacija, komplet in metoda za zmanjšanje intraokularnega tlaka
WO2011119969A1 (fr) 2010-03-26 2011-09-29 Inotek Pharmaceuticals Corporation Procédé de réduction de la pression intraoculaire chez l'homme à l'aide de n6-cyclopentyladénosine (cpa), de dérivés ou de promédicaments de cpa
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
WO2012080728A1 (fr) 2010-12-16 2012-06-21 Astrazeneca Ab Dérivé imidazo[4,5-c]quinolin-1-yle utile en thérapie
ES2627433T3 (es) 2010-12-17 2017-07-28 Sumitomo Dainippon Pharma Co., Ltd. Derivados de purina
WO2012107500A1 (fr) 2011-02-10 2012-08-16 Novartis Ag Composés de [1, 2, 4] triazolo [4, 3 -b] pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
WO2013038362A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituées en position 6 à activité tyrosine kinase
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
DK2807178T3 (en) 2012-01-26 2017-09-04 Inotek Pharmaceuticals Corp Anhydrous polymorphs of (2R, 3S, 4R, 5R) -5- (6- (cyclopentylamino) -9H-purin-9-yl) -3,4-dihydroxytetrahydrofuran-2-yl) methyl nitrate and processes for their preparation
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2968340A4 (fr) 2013-03-15 2016-08-10 Intellikine Llc Combinaison d'inhibiteurs de kinase et ses utilisations
SG11201506882YA (en) 2013-03-15 2015-09-29 Inotek Pharmaceuticals Corp Ophthalmic formulations
WO2015084804A1 (fr) 2013-12-03 2015-06-11 Novartis Ag Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5536419A (en) * 1978-09-08 1980-03-14 Yamasa Shoyu Co Ltd 2-substituted adenosine derivative and its preparation
AU8276187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE69932173T2 (de) * 1998-10-16 2007-06-06 Pfizer Inc. Adeninderivate
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives

Also Published As

Publication number Publication date
KR20030022758A (ko) 2003-03-17
ZA200202725B (en) 2003-04-08
HUP0203485A3 (en) 2005-02-28
HRP20020325A2 (en) 2004-04-30
HK1047942B (zh) 2005-04-01
NO20021751L (no) 2002-06-13
BR0014760A (pt) 2002-07-02
TR200201001T2 (tr) 2002-09-23
DE60026861T2 (de) 2006-09-21
PE20010753A1 (es) 2001-07-17
DE60026861D1 (de) 2006-05-11
WO2001027131A1 (fr) 2001-04-19
GT200000173A (es) 2002-04-05
SV2002000199A (es) 2002-02-05
CO5261621A1 (es) 2003-03-31
BG106567A (en) 2002-12-29
CA2387533C (fr) 2007-03-13
US6448236B1 (en) 2002-09-10
GEP20043324B (en) 2004-04-13
CN1378551A (zh) 2002-11-06
SK4742002A3 (en) 2003-05-02
ECSP003713A (es) 2002-05-23
AU7441200A (en) 2001-04-23
MA26829A1 (fr) 2004-12-20
NO20021751D0 (no) 2002-04-12
EP1220862B1 (fr) 2006-03-22
MY141512A (en) 2010-05-14
IL148331A0 (en) 2002-09-12
JP2003511460A (ja) 2003-03-25
EA004985B1 (ru) 2004-10-28
CZ20021179A3 (cs) 2003-04-16
OA12060A (en) 2006-05-03
NZ517294A (en) 2004-03-26
ES2257317T3 (es) 2006-08-01
MXPA02003750A (es) 2003-10-14
HK1047942A1 (en) 2003-03-14
HUP0203485A2 (hu) 2003-03-28
CR6607A (es) 2003-11-25
AU771531B2 (en) 2004-03-25
ATE321065T1 (de) 2006-04-15
PL354880A1 (en) 2004-03-22
IS6287A (is) 2002-02-26
AP2002002480A0 (en) 2002-06-30
EP1220862A1 (fr) 2002-07-10
JP3994008B2 (ja) 2007-10-17
EE200200194A (et) 2003-06-16
TNSN00203A1 (fr) 2002-05-30
AR026052A1 (es) 2002-12-26
CA2387533A1 (fr) 2001-04-19
PA8503601A1 (es) 2002-02-21
GT200000170A (es) 2002-04-03
CN1166678C (zh) 2004-09-15
EA200200360A1 (ru) 2002-10-31

Similar Documents

Publication Publication Date Title
IL148331A0 (en) Purine derivatives
IL146342A0 (en) Purine derivatives
GB9913932D0 (en) Purine derivatives
GC0000287A (en) Purine derivatives
EG23817A (en) 4-Phenyl-pyridine derivatives
IL150543A0 (en) Purine derivatives
GB0022695D0 (en) Purine Derivatives
IL152529A0 (en) Purine derivatives
IL148167A0 (en) Amino-triazolopyridine derivatives
GC0000183A (en) 3-Phenyl-pyridine derivatives
GC0000338A (en) 5-Phenyl-pyrimidine derivatives
HK1044940A1 (zh) 異噁唑咪唑羧酰胺衍生物
GC0000191A (en) 4-Phenyl-pyrimidine derivatives
GB9925880D0 (en) B-Carboline derivatives
GC0000256A (en) Ethanesulfonyl-piperidine derivatives
AP2001002327A0 (en) 1-Trifluoromethyl-4-hydroxy-7- piperidinylaminomethy lchroman derivatives
GB0014048D0 (en) Purine derivatives
GB0024920D0 (en) Purine derivatives
PL344600A1 (en) Adenosine a3
GB9907134D0 (en) Antimor napthylcombretastatin derivatives
HK1043987A1 (zh) 硫-羥吲衍生物

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)